Edgewise Therapeutics, Inc.
EWTX
$23.32
$0.341.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.60% | -1.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.97% | -7.29% | |||
| Operating Income | -9.97% | 7.29% | |||
| Income Before Tax | -12.60% | 11.48% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -12.60% | 11.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -12.60% | 11.48% | |||
| EBIT | -9.97% | 7.29% | |||
| EBITDA | -10.09% | 7.39% | |||
| EPS Basic | -12.03% | 19.77% | |||
| Normalized Basic EPS | -11.99% | 19.74% | |||
| EPS Diluted | -12.03% | 19.77% | |||
| Normalized Diluted EPS | -11.99% | 19.74% | |||
| Average Basic Shares Outstanding | 0.53% | 10.31% | |||
| Average Diluted Shares Outstanding | 0.53% | 10.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||